Casdin Capital, LLC
CIK 1534261 · Lihat di SEC EDGAR ↗
- Nilai Portofolio
- $2.0B
- Posisi
- 43
- Per tanggal
- 30 Juni 2026
#1.513 dari 9.443 berdasarkan nilai 13F · top 16.0%
Nilai portofolio QoQ: +51.3% 13F tidak mengungkapkan kas
- Bobot 10 kepemilikan teratas
- 77,36%
- Bobot 25 kepemilikan teratas
- 95,89%
- Posisi di atas 1%
- 20
- Jumlah posisi efektif
- 9,1
Berdasarkan kepemilikan ekuitas jangka panjang 13F saja (kas, obligasi, posisi jual tidak diungkapkan)
Perputaran Q2 2026: 8,4% Perkiraan pembelian $198.606.004 · penjualan $139.346.363
Kepemilikan median: 3,0 kuartal Dilacak Q4 2024–Q2 2026 · 59,7% masih dipegang
- Posisi baru
- 6
- Meningkat
- 9
- Menurun
- 3
- Tertutup
- 3
Di halaman ini
- Kinerja vs S&P Bagaimana portofolio 13F manajer ini berkinerja terhadap S&P 500.
- Rincian sektor Bagaimana portofolio terbagi di berbagai sektor pasar.
- Portofolio Setiap saham yang dilaporkan dimiliki oleh institusi ini, dari 13F terbarunya.
- Taruhan Bernilai Tinggi Kepemilikan yang paling terkonsentrasi pada manajer ini.
- Taruhan baru terbesar Posisi baru yang dibuka pada kuartal terakhir.
- Pergerakan Teratas Peningkatan dan penurunan posisi terbesar pada kuartal ini.
- Posisi yang keluar Posisi yang sepenuhnya dijual oleh manajer pada kuartal lalu.
- Terkait Orang di balik pengaju ini, jika kami dapat mencocokkannya.
Kinerja vs S&P 500
Tahunan: +31.5% · S&P 500: +18.0%
Perkiraan portofolio beli-dan-tahan yang dibangun dari snapshot 13F SEC triwulanan. Mengecualikan kas, posisi jual, opsi/derivatif, dan sekuritas non-13(f) — mencerminkan buku ekuitas long yang diungkapkan saja, bukan total AUM dana. Keterlambatan pengajuan SEC hingga 45 hari; ini bukan waktu yang dapat disalin secara real-time.
Cakupan yang dapat dihargai: 98,0% · Opsi dikecualikan: 0,1%
Rincian sektor
Healthcare
98,0%
Lainnya/Tidak terpetakan
2,0%
Portofolio lengkap 43 posisi
| Tipe | Rentetan | Tren 8 kuartal | |||||
|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines, Inc. - Common Stock | $482.682.924 | 24,16% | 2.577.333 | $232.037.290 | |||
| RLAY Relay Therapeutics, Inc. - Common Stock | $300.019.340 | 15,02% | 16.035.240 | $156.554.529 | Naik ×3 | ||
| WGS GeneDx Holdings Corp. - Class A Common Stock | $254.496.809 | 12,74% | 3.707.164 | $61.376.737 | Naik ×1 | ||
| BLFS BioLife Solutions, Inc. - Common Stock | $131.457.200 | 6,58% | 4.655.000 | $17.794.492 | Turun ×1 | ||
| ILMN Illumina, Inc. - Common Stock | $93.189.900 | 4,66% | 530.000 | $27.862.100 | |||
| LAB Standard BioTools Inc. - Common Stock | $73.042.478 | 3,66% | 88.783.856 | $-8.576.521 | |||
| GPCR Structure Therapeutics Inc. - American Depositary Shares | $63.062.250 | 3,16% | 1.175.000 | $6.427.250 | |||
| DNLI Denali Therapeutics Inc. - Common Stock | $52.597.400 | 2,63% | 2.045.000 | $17.269.400 | Naik ×1 | ||
| NGNE Neurogene Inc. - Common Stock | $48.601.603 | 2,43% | 1.545.361 | $19.967.125 | Naik ×2 | ||
| BEAM Beam Therapeutics Inc. - Common Stock | $46.332.000 | 2,32% | 1.350.000 | $14.161.500 | |||
| TXG 10x Genomics, Inc. - Common Stock | $40.257.000 | 2,02% | 1.050.000 | $-8.041.250 | Turun ×1 | ||
| SRRK Scholar Rock Holding Corporation - Common Stock | $36.575.000 | 1,83% | 665.000 | $19.369.000 | Naik ×2 | ||
| PSNL Personalis, Inc. - Common Stock | $34.170.000 | 1,71% | 2.550.000 | $23.978.000 | Naik ×1 | ||
| GRAL GRAIL, Inc. - Common Stock | $32.769.600 | 1,64% | 480.000 | $20.883.200 | Naik ×1 | ||
| GH Guardant Health, Inc. - Common Stock | $27.755.550 | 1,39% | 185.000 | $-1.341.000 | Turun ×2 | ||
| MAZE Maze Therapeutics, Inc. - Common Stock | $25.180.693 | 1,26% | 843.857 | $2.528.812 | Naik ×1 | ||
| HIMS Hims & Hers Health, Inc. Class A Common Stock | $24.269.000 | 1,21% | 700.000 | $9.737.000 | |||
| ALNY Alnylam Pharmaceuticals, Inc. - Common Stock | $22.577.250 | 1,13% | 75.000 | $-2.238.000 | |||
| TSHA Taysha Gene Therapies, Inc. - Common Stock | $22.132.500 | 1,11% | 3.250.000 | $7.605.000 | |||
| AGMB AgomAb Therapeutics NV - ADRs representing one common share. | $20.119.000 | 1,01% | 1.550.000 | $3.859.500 | |||
| SEPN Septerna, Inc. - Common Stock | $18.528.945 | 0,93% | 553.268 | $5.233.915 | |||
| Penerbit tidak dikenal (CUSIP: 698955101) | $17.672.535 | 0,88% | 645.690 | Naik ×1 | |||
| SION Sionna Therapeutics, Inc. - Common Stock | $17.596.000 | 0,88% | 400.000 | Naik ×1 | |||
| VCYT Veracyte, Inc. - Common Stock | $16.227.569 | 0,81% | 276.308 | $7.327.688 | |||
| ANL Adlai Nortye Ltd. - American Depositary Shares | $14.375.000 | 0,72% | 1.250.000 | $10.648.850 | Naik ×1 | ||
| PRME Prime Medicine, Inc. - Common Stock | $11.686.876 | 0,58% | 3.167.175 | $665.107 | |||
| ABSI Absci Corporation - Common Stock | $11.280.083 | 0,56% | 973.260 | $8.360.303 | |||
| DGX Quest Diagnostics Incorporated Common Stock | $10.597.500 | 0,53% | 50.000 | $798.500 | |||
| SRPT Sarepta Therapeutics, Inc. - Common Stock | $8.445.900 | 0,42% | 470.000 | ||||
| QURE uniQure N.V. - Ordinary Shares | $6.909.000 | 0,35% | 150.000 | Naik ×1 | |||
| NTLA Intellia Therapeutics, Inc. - Common Stock | $6.006.600 | 0,30% | 355.000 | $1.455.500 | |||
| MRNA Moderna, Inc. - Common Stock | $5.252.250 | 0,26% | 75.000 | $1.442.250 | |||
| IRON Disc Medicine, Inc. - Common Stock | $4.754.100 | 0,24% | 65.000 | $598.000 | |||
| GLUE Monte Rosa Therapeutics, Inc. - Common Stock | $4.501.539 | 0,23% | 186.014 | $1.441.609 | |||
| IPSC Century Therapeutics, Inc. - Common Stock | $3.009.066 | 0,15% | 1.228.190 | $233.357 | |||
| CTNM Contineum Therapeutics, Inc. - Common stock | $2.431.178 | 0,12% | 148.333 | $493.949 | |||
| BBOT BridgeBio Oncology Therapeutics, Inc. - Common Stock | $2.151.217 | 0,11% | 282.312 | $-375.475 | |||
| EDIT Editas Medicine, Inc. - Common Stock | $1.441.800 | 0,07% | 445.000 | Naik ×1 | |||
| PACB Pacific Biosciences of California, Inc. - Common Stock | $1.215.929 | 0,06% | 723.767 | $260.557 | |||
| Penerbit tidak dikenal (CUSIP: 485925101) | $1.192.500 | 0,06% | 50.000 | Naik ×1 | |||
| RXRX Recursion Pharmaceuticals, Inc. - Class A Common Stock | $606.735 | 0,03% | 165.323 | $99.193 | |||
| DNA Ginkgo Bioworks Holdings, Inc. Class A Common Stock | $361.646 | 0,02% | 36.493 | $137.944 | |||
| TNYA Tenaya Therapeutics, Inc. - Common Stock | $267.531 | 0,01% | 361.969 | $16.904 | |||
| Tidak ada hasil | |||||||
Kepemilikan dengan keyakinan
Posisi meningkat selama 3+ kuartal berturut-turut.
Jumlah saham dilaporkan dalam pengajuan 13F (tidak disesuaikan split)
| Sekuritas | Nilai | % dari portofolio | Rentetan |
|---|---|---|---|
| RLAY | $300.019.340 | 15,02% | naik ×3 |
Taruhan baru terbesar
Posisi baru dibuka kuartal ini, terbesar diurutkan pertama.
Penggerak teratas (QoQ)
| Sekuritas | Aksi | Saham Δ | Nilai Δ |
|---|---|---|---|
| RVMD | Hanya pergerakan harga | +0 | +$232.0M |
| RLAY | Beli lebih banyak | +1.6M | +$156.6M |
| WGS | Beli lebih banyak | +700K | +$61.4M |
| ILMN | Hanya pergerakan harga | +0 | +$27.9M |
| PSNL | Beli lebih banyak | +950K | +$24.0M |
| GRAL | Beli lebih banyak | +250K | +$20.9M |
| NGNE | Beli lebih banyak | +125K | +$20.0M |
| SRRK | Beli lebih banyak | +315K | +$19.4M |
| BLFS | Dipangkas | -1.3M | +$17.8M |
| DNLI | Beli lebih banyak | +205K | +$17.3M |
Posisi yang keluar
Termasuk peristiwa perusahaan (merger, delisting) — tidak semua keluar adalah penjualan
Posisi tertutup mencerminkan perubahan pelaporan 13F; bagi manajer indeks, ini sering kali mekanis (penghapusan pencatatan, M&A, penyeimbangan ulang indeks), bukan keputusan aktif.
| Sekuritas | Kuartal | Saham sebelumnya | Nilai sebelumnya | Harga sejak keluar |
|---|---|---|---|---|
| RNA | 31 Maret 2026 | 1.000.000 | $72.130.000 | 1,9% |
| VERV | 30 Sep. 2025 | 4.095.571 | $45.993.262 | Tidak lagi dilacak |
| BPMC | 30 Juni 2025 | 326.378 | $28.887.717 | Tidak lagi dilacak |
| SPRY | 31 Maret 2026 | 1.600.000 | $18.640.000 | -23,7% |
| CDXS | 30 Sep. 2025 | 7.200.000 | $17.568.000 | -33,8% |
| SRPT | 30 Sep. 2025 | 990.097 | $16.930.659 | -0,6% |
| UNH | 31 Maret 2026 | 50.000 | $16.505.500 | 45,0% |
| QGEN | 30 Juni 2026 | 360.000 | $14.414.400 | 14,4% |
| NTLA | 30 Juni 2025 | 2.000.000 | $14.220.000 | 35,1% |
| TEM | 30 Juni 2026 | 294.127 | $13.300.423 | 14,6% |
| DXCM | 31 Maret 2026 | 175.000 | $11.614.750 | 45,0% |
| CI | 31 Maret 2026 | 40.000 | $11.009.200 | 4,3% |
| ONC | 30 Juni 2025 | 40.000 | $10.886.800 | 54,0% |
| TSVT | 30 Juni 2025 | 2.000.000 | $9.880.000 | Tidak lagi dilacak |
| INCY | 31 Maret 2026 | 100.000 | $9.877.000 | 36,1% |
| MLTX | 30 Juni 2026 | 450.000 | $8.388.000 | -15,9% |
| GEHC | 30 Juni 2025 | 100.000 | $8.071.000 | 1,0% |
| LLY | 30 Sep. 2025 | 8.500 | $6.626.005 | 66,2% |
| FDMT | 31 Maret 2025 | 1.150.000 | $6.405.500 | 386,2% |
| MRNA | 30 Juni 2025 | 225.000 | $6.378.750 | 419,2% |
| SNDX | 30 Sep. 2025 | 650.000 | $6.084.000 | 32,2% |
| FTRE | 31 Maret 2025 | 275.000 | $5.128.750 | 140,9% |
| EXAS | 31 Des. 2025 | 90.000 | $4.923.900 | Tidak lagi dilacak |
| LEGN | 31 Maret 2026 | 215.000 | $4.674.100 | 23,9% |
| VSTM | 30 Juni 2025 | 600.000 | $3.618.000 | 71,3% |
| AGIO | 30 Sep. 2025 | 100.000 | $3.326.000 | -15,0% |
| SLDB | 30 Juni 2025 | 775.000 | $2.867.500 | 90,7% |
| TDOC | 30 Juni 2025 | 300.000 | $2.388.000 | -23,2% |
| DYN | 30 Juni 2025 | 100.000 | $1.046.000 | 173,3% |
| TNGX | 30 Juni 2025 | 125.000 | $171.250 | 377,0% |
| KRON | 30 Juni 2025 | 123.839 | $102.167 | Tidak lagi dilacak |